Prostate Specific Antigen News and Research

RSS

Negative aspects of prostate cancer screening acceptable

The negative aspects of screening for prostate cancer may be acceptable, since screening halves mortality from the disease. This is the conclusion of a thesis presented at the University of Gothenburg, Sweden.

12 Jan 2011

Janssen files abiraterone acetate NDS with Health Canada for metastatic, advanced prostate cancer

Janssen Inc. has filed a New Drug Submission (NDS) to Health Canada for the investigational drug abiraterone acetate administered with prednisone for the treatment of metastatic, advanced prostate cancer in patients who have received prior chemotherapy containing a taxane. Submissions for abiraterone acetate have also been filed with health authorities in the United States and Europe.

23 Dec 2010

New study suggests PSA test effective for men with prostate cancer

The PSA screening test for prostate cancer is not perfect. It can indicate cancer when none is present and miss life-threatening tumors. But a new study suggests the test is more reliable in men taking dutasteride (Avodart®), a drug widely prescribed to shrink an enlarged prostate gland.

17 Dec 2010

High-dose rate brachytherapy procedure to treat prostate cancer

Beaumont Hospital radiation oncologists have launched a research study to treat men with low to intermediate risk prostate cancer with a single dose of radiation.

17 Dec 2010

DeCODE Genetics identify SNPs to derive PSA threshold for diagnosing prostrate cancer

Scientists from deCODE genetics and academic colleagues from Iceland, the UK, US, Netherlands, Spain and Romania today report the discovery of a set of single-letter variations in the sequence of the human genome that impact individual baseline levels of prostate specific antigen, or PSA.

16 Dec 2010

Prostate cancer study identifies 295 genes associated with clinical recurrence following radical prostatectomy

Genomic Health, Inc. today announced the first results of a large prostate cancer study that identified 295 genes strongly associated with clinical recurrence following radical prostatectomy. Top-line findings from this study, which applied the same RT-PCR technology used in Genomic Health's Oncotype DX® breast and colon cancer tests, will be presented today at the Society for Urologic Oncology (SUO) annual meeting.

13 Dec 2010

Expert discusses androgen deprivation therapy for prostate cancer

A common prostate cancer treatment, the ‘androgen deprivation therapy’ has often been prescribed for low-risk prostate cancer patients. This therapy for treating prostate cancer had previously been blamed for increased risk of cardiovascular disease and heart conditions.

9 Dec 2010

Researchers develop imaging technology that can accurately identify prostate cancer

Prostate cancer is the most common type of cancer among men, but its diagnosis has up to now been inaccurate and unpleasant. Researchers at Eindhoven University of Technology in the Netherlands, in cooperation with AMC Amsterdam, have developed an imaging technology that can accurately identify tumors.

8 Dec 2010

Companies, media organizations join Georgia Prostate Cancer Coalition to launch pledge campaign

Prostate cancer is a serious health concern in Georgia. According to the American Cancer Society, the state of Georgia ranks 11th in number of estimated deaths per capita from the disease. In an effort to raise awareness about prostate cancer and ensure more men commit to be informed and screened, several companies and media organizations have joined the Georgia Prostate Cancer Coalition in launching a pledge campaign.

4 Dec 2010

FDA advisory committee votes against Avodart sNDA for prostate cancer risk reduction

GlaxoSmithKline today announced the results of a U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) meeting to discuss the supplemental New Drug Application (sNDA) for Avodart® (dutasteride) for reducing the risk of prostate cancer in men at risk for the disease, defined as those who have had a prior negative biopsy due to clinical concern and have an elevated serum prostate-specific antigen (PSA).

2 Dec 2010

Active surveillance improves quality of life in low-risk prostate cancer patients

In a study that compared initial treatment strategies for low-risk prostate cancer among men 65 years old, active surveillance showed higher measures on quality of life compared to an initial treatment such as radical prostatectomy, although the optimal strategy was highly dependent on individual patient preferences for surveillance or treatment, according to a study in the December 1 issue of JAMA.

1 Dec 2010

New anti-cancer drug targeting vitamin D receptor reduces PSA level in HRPC

A new anti-cancer drug aimed at vitamin D receptors on cancer cells has prompted encouraging responses in the levels of PSA (prostate specific antigen) in men with prostate cancer that has become resistant to hormonal therapies.

18 Nov 2010

Potential new biomarkers for very early prostate cancer

A new study presented at the National Cancer Research Institute (NCRI) conference in Liverpool next week has found potential new biomarkers for very early prostate cancer in men with no symptoms of the disease.

8 Nov 2010

Level of prostate-specific protein after salvage radiation therapy predicts mortality and disease progression

Removal of the prostate gland often eradicates early-stage cancer. But patients whose cancer has spread may need to follow up with what is known as salvage radiation therapy. Researchers at Fox Chase have now determined a better way to monitor outcomes after this procedure.

4 Nov 2010

Gene fusion prostate cancers susceptible to secondary mutations

Scientists at Weill Cornell Medical College have taken an important step toward a better understanding of prostate cancer by uncovering evidence that it is not one disease, as previously believed, but rather several factors which can be measured and, in the future, destroyed by targeted therapy.

4 Nov 2010

AHRQ study finds prostate cancer mortality rate declines by 45%

According to the U.S. Agency for Healthcare Research and Quality (AHRQ), compared to men in 1999, American men in 2006 that were fighting prostate cancer were 45% less likely to die from the disease.

3 Nov 2010

PSA test helps detect prostate cancer before it spreads

In addition to saving lives, a new study indicates routine prostate-specific antigen (PSA) testing improves quality of life by substantially reducing the risk that prostate cancer will spread to other parts of the body.

27 Oct 2010

Routine prostate cancer screening reduces metastasis risk

Men treated for prostate cancer who were diagnosed after the start of routine screening had a significantly reduced risk of the disease spreading to other parts of the body (metastases) within 10 years of treatment, compared to men who were treated prior to the use of routine screening, according to the first study-of-its-kind presented November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

Robot-assisted surgery effective for five-year prostate cancer control: Study

A first-ever, long-term study of patients who underwent robot-assisted surgery to remove their cancerous prostates found that nearly 87 percent of them had no recurrence of the disease after five years.

19 Oct 2010

Scientists identify protein in urine can indicate prostate cancer risk

Cancer research UK scientists have shown that a protein in urine could be a powerful indicator of prostate cancer risk, according to a study published in PLoS ONE.

14 Oct 2010